Long-term Safety and Effectiveness of Growth Hormone With GHD, TS, CRF, SGA , ISS and PWS in Children

Last updated: February 17, 2021
Sponsor: LG Chem
Overall Status: Active - Recruiting

Phase

N/A

Condition

Turner Syndrome

Severe Short Stature

Idiopathic Short Stature

Treatment

N/A

Clinical Study ID

NCT01604395
LG-HGOS001
  • Ages > 2
  • All Genders

Study Summary

The purpose of this study is to evaluate the long-term safety and effectiveness of growth hormone (Eutropin Inj./Eutropin plus Inj.) treatment with GHD (Growth Hormone Deficiency), TS (Turner Syndrome),CRF (Chronic Renal Failure), SGA (Small for Gestational Age), and ISS (Idiopathic Short Stature).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • short stature children aged 2 years or more

  • children with GHD,TS, CRF, SGA or ISS

  • written informed consent from the person, person's parent or legal guardian

Study Design

Total Participants: 6000
Study Start date:
January 01, 2012
Estimated Completion Date:
December 31, 2032

Connect with a study center

  • Seoul National University Hospital

    Seoul,
    Korea, Republic of

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.